Home>Topics>Stocks>GlaxoSmithKline PLC

GlaxoSmithKline PLC GSK

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. China hands drugmaker GSK record $489 million fine for paying bribes

      Headlines

      Fri, 19 Sep 2014

      SHANGHAI/LONDON (Reuters) - China fined GlaxoSmithKline Plc a record 3 billion yuan ($489 million) on Friday for paying bribes to doctors to use its drugs, underlining the risks of doing business there while also ending a damaging chapter for the British drugmaker.

    2. GSK ex-China head Mark Reilly to be deported from China, won't face jail time - source

      Headlines

      Fri, 19 Sep 2014

      SHANGHAI, Sept 19 (Reuters) - Mark Reilly, the former China head of British drugmaker GlaxoSmithKline PLC , will be deported from China and will not face jail time in the country, according to a source with direct knowledge of the matter.

    3. China fines GSK $489 mln, jails executives -Xinhua

      Headlines

      Fri, 19 Sep 2014

      BEIJING, Sept 19 (Reuters) - China has fined British pharmaceuticals giant GlaxoSmithKline Plc 3 billion yuan ($488.8 million) for paying out bribes in what is a record penalty for China, state news agency Xinhua said on Friday.

    4. Terrific Stocks On Sale: Part 1

      Headlines

      Mon, 15 Sep 2014

      good value to long term investors. Introducing first: from United Kingdom representing the Healthcare sector, GlaxoSmithKline PLC (NYSE: GSK ). Current Situation : Whichever way you see it, the stock has taken a hammering. It's down

    5. Exclusive: GSK China consumer healthcare unit linked to DOJ probe in 2012

      Headlines

      Tue, 9 Sep 2014

      SHANGHAI/WASHINGTON (Reuters) - A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance

    6. India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden

      Headlines

      Mon, 1 Sep 2014

      MUMBAI, Sept 1 (Reuters) - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc 's Advair, a move that will further dent sales of the British firm's top-selling product.

    7. New Morningstar Analyst Report for GlaxoSmithKline PLC

      Stock Reports

      Thu, 21 Aug 2014

      Even though device patents may hold off generic Advair competition until 2016, these patents are weaker than composition-of-matter patents, which opens the door to generics in the near term, especially in Europe, where regulators seems more willing to approve generic inhaled drugs.Pricing pressure

    8. GSK-linked investigators stand trial in China in closely watched case

      Headlines

      Thu, 7 Aug 2014

      SHANGHAI (Reuters) - A British investigator and his American wife will stand trial in Shanghai on Friday in a case that is seen as key to a bribery investigation against GlaxoSmithKline Plc and has unnerved the growing community of corporate sleuths in China.

    9. GSK-linked investigators stand trial in China in closely watched case

      Headlines

      Thu, 7 Aug 2014

      SHANGHAI, Aug 8 (Reuters) - A British investigator and his American wife will stand trial in Shanghai on Friday in a case that is seen as key to a bribery investigation against GlaxoSmithKline Plc and has unnerved the growing community of corporate sleuths in China.

    10. ChemoCentryx says partner GSK returns rights to bowel disease drug

      Headlines

      Wed, 18 Sep 2013

      Sept 18 (Reuters) - ChemoCentryx Inc said partner GlaxoSmithKline Plc returned the rights to its inflammatory bowel disease drug, the company's lead product candidate.

    « Prev123Next »
    Content Partners